CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

CA Cancer J Clin 2005; 55:352-367
doi: 10.3322/canjclin.55.6.352
© 2005 American Cancer Society
This Article
Right arrow Full Text Freely available
Right arrow Full Text (PDF) Freely available
Right arrow Freely available CME: Take the course for this article:
 Multimodality Approaches for Pancreatic Cancer
Right arrow Submit a letter to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yang, G. Y.
Right arrow Articles by Thomas, C. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, G. Y.
Right arrow Articles by Thomas, C. R., Jr.

Multimodality Approaches for Pancreatic Cancer

Gary Y. Yang, MD, Timothy D. Wagner, MD, MBA, Martin Fuss, MD and Charles R. Thomas, Jr., MD


Dr. Yang is Assistant Professor, Residency Program Director, Department of Radiation Medicine, Roswell Park Cancer Institute, Buffalo, NY.
Dr. Wagner is Chief Resident, Department of Radiation Medicine, Roswell Park Cancer Institute, Buffalo, NY.
Dr. Fuss is Associate Professor, Department of Radiation Oncology, University of Texas Health Science Center at San Antonio, San Antonio Cancer Institute, San Antonio, TX.
Dr. Thomas is Professor and Chairman, Department of Radiation Medicine, Oregon Health & Science University, Portland, OR.

The role of combined-modality therapy for pancreatic cancer is evolving with the recent development and completion of major, multi-institutional clinical trials. One of the challenges for the busy clinician is to appreciate the variation in staging, surgical expertise, and application of either definitive chemoradiotherapy or adjuvant chemoradiotherapy for local and/or regionally advanced disease. Our aim is to summarize the current state-of-the-art management and future directions regarding the multimodality approach to pancreatic cancer.




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
L. Benkoel, J.-P. Bernard, M.-J. Payan-Defais, L. Crescence, C. Franceschi, M. Delmas, M. Ouaissi, B. Sastre, J. Sahel, A.-M. Benoliel, et al.
Monoclonal antibody 16D10 to the COOH-terminal domain of the feto-acinar pancreatic protein targets pancreatic neoplastic tissues
Mol. Cancer Ther., February 1, 2009; 8(2): 282 - 291.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by American Cancer Society.